In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jstreetdata.com Inc.

This article was originally published in Start Up

Executive Summary

JStreetdata.com Inc. is positioning itself as a provider of infrastructure that can help health care companies do more effective market-research. It's focusing particularly on the recruiting and data-management aspects of research. Customers can use the firm's software to adapt their traditional survey instruments to the Internet, and they can pick from JStreet's databases the types of physicians they'd like to have surveyed. JStreet is also conducting syndicated studies of therapeutic areas; it hopes to sell these widely.

You may also be interested in...



E-Medical Market Research

Internet-based market research has become the norm in many areas of commerce, but the pharmaceutical industry is only just beginning to adopt the practice. The trend is being pushed forward by young companies that claim they can help drugmakers get from doctors the sorts of information they value--only more efficiently and cost-effectively than ever before. The web will also enable the collection of new types of information and insights, these start-ups claim.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel